Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dexmedetomidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 4/20 | 0.37 |
| ▸ | ADRA2B known ✓ | P18089 | 4/20 | 0.37 |
| ▸ | ADRA2C known ✓ | P18825 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexmedetomidine SCHEMBL22476080 | 0.86 | ADRA2A (0.40) | NAPRTLMNATP53TSHRKMT2A | |
| SCHEMBL9290482 | 0.85 | TSHR (0.40) | ALDH1A1KDM4EHPGDNAPRTLMNA | |
| Medetomidine SCHEMBL22616184 | 0.84 | ADRA2A (0.43) | TP53TSHRNPC1RAB9ACYP3A4 | |
| Dexmedetomidine SCHEMBL22616211 | 0.84 | ADRA2A (0.43) | TP53TSHRNPC1RAB9ACYP3A4 | |
| Dexmedetomidine SCHEMBL22616265 | 0.83 | ADRA2A (0.42) | ALDH1A1NAPRTLMNATP53TSHR | |
| Medetomidine SCHEMBL22616262 | 0.83 | LMNA (0.47) | ALDH1A1KDM4ENAPRTSMN1; SMN2LMNA | |
| Dexmedetomidine SCHEMBL22616256 | 0.83 | LMNA (0.47) | ALDH1A1KDM4ENAPRTSMN1; SMN2LMNA | |
| Medetomidine SCHEMBL26432 | 0.83 | ADRA2A (0.50) | TP53TSHRCYP3A4CYP2C9CYP1A2 | |
| Medetomidine SCHEMBL787913 | 0.83 | ADRA2A (0.50) | TP53TSHRCYP3A4CYP2C9CYP1A2 | |
| Dexmedetomidine SCHEMBL119382 | 0.83 | ADRA2A (0.50) | TP53TSHRCYP3A4CYP2C9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197684-A1 | NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENS | OAKTREE FUND ADMINISTRATION, LLC | 2024-06-20 | — | — | US | disclosed |
| US-11998529-B2 | Non-sedating dexmedetomidine treatment regimens | BIOXCEL THERAPEUTICS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-11998528-B1 | Non-sedating dexmedetomidine treatment regimens | BIOXCEL THERAPEUTICS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240173299-A1 | NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENS | OAKTREE FUND ADMINISTRATION, LLC | 2024-05-30 | — | — | US | disclosed |
| EP-4363057-A1 | METHODS FOR TREATING DEPRESSIVE STATES | BioXcel Therapeutics, Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| US-20240139169-A1 | METHODS AND COMPOSITIONS FOR TREATING AGITATION | OAKTREE FUND ADMINISTRATION, LLC | 2024-05-02 | — | — | US | disclosed |
| CN-117750956-A | Methods for treating depressive states | 比奥克斯塞尔医疗股份有限公司 | 2024-03-22 | — | — | CN | disclosed |
| WO-2024055042-A1 | METHODS FOR TREATING AGITATION IN COMMUNITY SETTINGS | BIOXCEL THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050028-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE STRESS DISORDER | BIOXCEL THERAPEUTICS, INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| US-11890272-B2 | Non-sedating dexmedetomidine treatment regimens | BIOXCEL THERAPEUTICS, INC. (US) | 2024-02-06 | — | — | US | disclosed |
| US-20220160629-A1 | FILM FORMULATIONS CONTAINING DEXMEDETOMIDINE AND METHODS OF PRODUCING THEM | OAKTREE FUND ADMINISTRATION, LLC | 2022-05-26 | — | — | US | disclosed |
| EP-3999058-A2 | NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENS | Bioxcel Therapeutics, Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
| US-20220142918-A1 | FILM FORMULATIONS CONTAINING DEXMEDETOMIDINE AND METHODS OF PRODUCING THEM | OAKTREE FUND ADMINISTRATION, LLC | 2022-05-12 | — | — | US | disclosed |
| CN-114375191-A | Non-sedating dexmedetomidine treatment regimen | 比奥克斯塞尔医疗股份有限公司 | 2022-04-19 | — | — | CN | disclosed |
| CN-112888431-A | Dexmedetomidine-containing film preparation and method for producing the same | 比奥克斯塞尔医疗股份有限公司 | 2021-06-01 | — | — | CN | disclosed |
| EP-3813802-A1 | FILM FORMULATIONS CONTAINING DEXMEDETOMIDINE AND METHODS OF PRODUCING THEM | Bioxcel Therapeutics, Inc. (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20210077388-A1 | FILM FORMULATIONS CONTAINING DEXMEDETOMIDINE AND METHODS OF PRODUCING THEM | OAKTREE FUND ADMINISTRATION, LLC | 2021-03-18 | — | — | US | disclosed |
| WO-2021016112-A2 | NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENS | BIOXCEL THERAPEUTICS, INC. (US) | 2021-01-28 | — | — | WO | disclosed |
| US-20200345635-A1 | FILM FORMULATIONS CONTAINING DEXMEDETOMIDINE AND METHODS OF PRODUCING THEM | OAKTREE FUND ADMINISTRATION, LLC | 2020-11-05 | — | — | US | disclosed |
| US-10792246-B2 | Film formulations containing dexmedetomidine and methods of producing them | BIOXCEL THERAPEUTICS, INC. (US) | 2020-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11998528-B1 | Non-sedating dexmedetomidine treatment regimens | CHRNA3, DRD2, CHRNA10 | ADRA2A 35/4885ADRA2B 59/4885ADRA2C 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.